Chen Zhou, Jin Dacheng, Hu Jinjing, Guan Defeng, Bai Qizhou, Gou Yunjiu
Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.
The Third Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Front Cell Infect Microbiol. 2025 Jun 3;15:1563061. doi: 10.3389/fcimb.2025.1563061. eCollection 2025.
Gastric cancer, a prevalent malignancy globally, is influenced by various factors. The imbalance in the gut microbiome and the existence of particular intratumoural microbiota could have a strong connection with the onset and progression of gastric cancer. High-throughput sequencing technology and bioinformatics analysis have revealed a close correlation between abnormal abundance of specific microbial communities and the risk of gastric cancer. These microbial communities contribute to gastric cancer progression through mechanisms including increasing cellular genomic damage, inhibiting DNA repair, activating abnormal signaling pathways, exacerbating tumor hypoxia, and shaping a tumor immune-suppressive microenvironment. This significantly impacts the efficacy of gastric cancer treatments, including chemotherapy and immunotherapy. Probiotic, prebiotic, antibiotic, carrier-based, dietary interventions, fecal microbiota transplantation, and traditional Chinese medicine show potential applications in gastric cancer treatment. However, the molecular mechanisms regarding dysbiosis of microbiota, including gut microbiota, and intra-tumoral microbiota during the progression of gastric cancer, as well as the therapeutic efficacy of microbiota-related applications, still require extensive exploration through experiments.
胃癌是全球一种常见的恶性肿瘤,受多种因素影响。肠道微生物群的失衡以及特定肿瘤内微生物群的存在可能与胃癌的发生和进展密切相关。高通量测序技术和生物信息学分析揭示了特定微生物群落的异常丰度与胃癌风险之间的密切相关性。这些微生物群落通过增加细胞基因组损伤、抑制DNA修复、激活异常信号通路、加剧肿瘤缺氧以及塑造肿瘤免疫抑制微环境等机制促进胃癌进展。这对包括化疗和免疫疗法在内的胃癌治疗效果产生了重大影响。益生菌、益生元、抗生素、载体疗法、饮食干预、粪便微生物群移植和中药在胃癌治疗中显示出潜在应用价值。然而,关于微生物群失调的分子机制,包括胃癌进展过程中肠道微生物群和肿瘤内微生物群的失调,以及微生物群相关应用的治疗效果,仍需要通过实验进行广泛探索。